This accredited activity highlights key aspects from the virtual live where 2 experts discuss the prognostic relevance of B7-H3 for patients with previously treated extensive-stage small cell lung cancer and practical guidance for incorporating these novel therapies into current treatment paradigms. As a result of this educational curriculum, learners should be better able to: 1. Specify how B7-H3 over expression is relevant to ES-SCLC prognosis and treatment; 2. Interpret the clinical evidence for emerging B7H3 directed ADCs in patients with previously treated ES-SCLC; and, 3. Translate current evidence and clinical considerations for B7-H3 targeted ADCs into treatment algorithms for patients with ES-SCLC. Learners have access to downloadable materials.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- includes Online course / module
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedDec 4, 2025
-
Last day to claim creditDec 4, 2026 8 weeks left
-
Global Learning Collaborative Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
-
Physicians’ Education Resource Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes
-
PRIME Education, Inc. (PRIME®) Evolving Treatment Strategies in ES-SCLC: From Emerging Evidence to Patient Care
-
Answers in CME Inc. (AiCME) New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3 Directed ADCs
-
Answers in CME Inc. (AiCME) 30-Minute Power Briefing: B7-H3-Directed ADCs in Previously Treated ES-SCLC – What’s New and What’s Now?
-
Answers in CME Inc. (AiCME) Rapid Roundup 2025 in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care
